The NIH Guide announces scientific initiatives and provides policy and administrative information to individuals and organizations who need to be kept informed of opportunities, requirements, and changes in extramural programs administered by the National Institutes of Health.

Vol. 17, No. 19
May 27, 1988
DATED ANNOUNCEMENTS (RFPs AND RFAs)

SINGLE PHOTON RADIOPHARMACEUTICALS FOR FUNCTION, METABOLISM
AND TISSUE LOCALIZATION (RFP)............................................ 1
National Cancer Institute
Index: CANCER

EVALUATION OF EXPERIMENTAL BENZODIAZEPINES FOR DEVELOPMENT
OF TOLERANCE TO ANTICONVULSANT ACTIVITY (RFP)....................... 1
National Institute of Neurological and Communicative Disorders
and Stroke
Index: NEUROLOGICAL, COMMUNICATIVE DISORDERS AND STROKE

CENTERS FOR INTERDISCIPLINARY RESEARCH ON IMMUNOLOGIC DISEASES (RFA)...... 2
National Institute of Allergy and Infectious Diseases
Index: ALLERGY AND INFECTIOUS DISEASES

NOTICE - MACROMOLECULAR STRUCTURE REFINEMENT WORKSHOP FOR
BIOMEDICAL RESEARCHERS ..................................................... 3
Division of Research Resources
Index: RESEARCH RESOURCES

ERRATUM

INVESTIGATIONS INTO METHODS THAT REPLACE OR REDUCE ANIMALS USED
IN RESEARCH OR LESSEN THEIR PAIN AND DISTRESS .......................... 4
Alcohol, Drug Abuse, and Mental Health Administration
Index: ALCOHOL, DRUG ABUSE AND MENTAL HEALTH
SINGLE PHOTON RADIOPHARMACEUTICALS FOR FUNCTION, METABOLISM AND TISSUE LOCALIZATION

RFP AVAILABLE: NCI-CM-97570-74
P.T. 34; K.W. 0740025, 0706030

National Cancer Institute

The Diagnostic Imaging Research Branch, Division of Cancer Treatment, National Cancer Institute, is seeking contractors with the expertise to develop and evaluate potential radiopharmaceuticals labeled with Technetium-99m and/or Iodine-123 for the purpose of diagnostic imaging using Single Photon Emission Computed Tomography (SPECT). The Government anticipates that three (3) awards will be made. It is anticipated that the resulting contracts will be awarded on an incrementally funded basis for a period of 36 months.

RFP NCI-CM-97570-74 for the work described above will be available to interested offerors on or about June 7, 1988, with a due date for receipt of proposals of July 29, 1988. Copies of the RFP may be obtained by sending a written request to the following:

Odessa S. Henderson
Contract Specialist
Treatment Contracts Section, RCB
National Cancer Institute, NIH
Blair Building, Room 228
Bethesda, Maryland 20892
Telephone: (301) 427-8737

EVALUATION OF EXPERIMENTAL BENZODIAZEPINES FOR DEVELOPMENT OF TOLERANCE TO ANTICONVULSANT ACTIVITY

RFP AVAILABLE: NIH-NINCDS-88-14
P.T. 34; K.W. 0740010, 0710080

National Institute of Neurological and Communicative Disorders and Stroke

The National Institute of Neurological and Communicative Disorders and Stroke (NINCDS), NIH, has a requirement and plans to issue a Request for Proposals (RFP) entitled, "Evaluation of Experimental Benzodiazepines for Development of Tolerance to Anticonvulsant Activity." Proposals will be solicited for the evaluation of unknown benzodiazepine compounds, using an existing animal model developed for this purpose, to determine if tolerance development to anticonvulsant activity occurs. The animal model, which was developed in the mouse species using pentylenetetrazol, will be utilized for all evaluations. All candidate benzodiazepine compounds, and information related to the supply, purity, storage and preparation of the compounds, will be supplied to the Contractor by the NINCDS. It is estimated that five (5) to fifteen (15) compounds per year will be supplied for evaluation.

The Government anticipates one contract award for a performance period of two (2) years.

Prospective offerors are advised that since performance of the work under this project will involve use of animals, the awardee will be required to comply with the DHHS/PHS policies and provisions for the "Use and Care of Live Vertebrate Animals." In addition, prospective offerors are expected to have in-house: 1) the animal and laboratory facilities and equipment necessary for the performance of work; and 2) a senior Ph.D. level pharmacologist with expertise in neuroscience or neuropharmacology and who has experience in the area of drug tolerance.

This is an announcement of an anticipated Request for Proposals (RFP). RFP No. NIH-NINCDS-88-14 will be issued on or about May 25, 1988, with a closing date for receipt of proposals tentatively set for July 22, 1988.

To receive a copy of the RFP, please supply this office with two self-addressed mailing labels. Requests must cite the RFP number referenced above and will be honored if received within 30 calendar days after the solicitation issue date. Since a limited number of RFP copies will be printed, requests will be filled on a first-come, first-serve basis until the
supply is exhausted. Request for copies of the RFP should be sent to the following address:

Contracts Management Branch, DEA
National Institute of Neurological and Communicative Disorders and Stroke, NIH
Federal Building, Room 901
7550 Wisconsin Avenue
Bethesda, Maryland 20892

CENTERS FOR INTERDISCIPLINARY RESEARCH ON IMMUNOLOGIC DISEASES

RFA AVAILABLE: 88-AI-07
P.T. 04; K.W. 0710070, 0710030, 0785035
National Institute of Allergy and Infectious Diseases
Application Receipt Date: October 14, 1988

BACKGROUND INFORMATION

The Clinical Immunology and Immunopathology Branch of the Immunology, Allergic and Immunologic Diseases Program (IAIDP) of the National Institute of Allergy and Infectious Diseases (NIAID) supports research on cellular and molecular mechanisms of immunologic diseases and the application of this knowledge to clinical problems. For this purpose, 5 Centers for Interdisciplinary Research on Immunologic Diseases (CIRID) are currently funded. This request for applications (RFA) is intended to encourage the development of applications from collaborative basic science and clinical investigative groups, and to coordinate the submission of new and renewal CIRID applications providing equitable opportunity for both to compete for funds currently available for existing programmatic activities concerned with the study of immunologic diseases. Of the 5 currently funded CIRIDs, support for one is scheduled to conclude in 1988.

RESEARCH GOALS AND SCOPE

Since the inception of the CIRID program in 1978, NIAID's fundamental objective for the CIRID program remains unchanged: acceleration of the application of knowledge on the immune system, emerging from relevant biomedical sciences, to clinical investigations concerned with immunologic disorders, a segment of which can be devoted to asthma and allergic diseases. The scope of these CIRIDs is intended to include studies of immunologic responses aimed at defining etiological factors and pathogenetic mechanisms.

Research approaches in this area include basic and clinical immunology studies of acquired and inherited diseases associated with dysfunctions of the immune system (AIDS and Childhood Immunodeficiencies); immunopathology studies of the genetics, cytology, biochemistry, physiology, and pharmacology of the immune system and its disorders (autoimmune disorders; immune relationships in diabetes, acute and chronic inflammation (mediators, anti-inflammatory agents, chemistry and disorders of the complement system, and mechanisms of phagocytosis); and investigations concerned with allergic and hypersensitivity mechanisms (asthma, allergic disorders and drug reactions).

In addition, a unique feature of the CIRID program is the requirement to implement educational or community activities. Within the research framework of the Center, a variety of outreach and demonstration projects may be supported.

MECHANISM OF SUPPORT

Centers are awarded to an institution on behalf of a program director for the support of a broadly-based, multidisciplinary or interdisciplinary, long-term research program which has a specific major objective or basic theme. A Center generally involves the organized efforts of groups of investigators, members of which conduct research projects related to the overall program objective. The grant can provide support for the projects and for certain core resources shared by individuals in a program where the sharing facilitates the total research effort. Overall, each component project supported under a Center grant, whether for basic research, clinical research or outreach demonstration projects, is expected to contribute to and be directly related to the overall common goal; the projects should demonstrate an essential element of unity and interdependence. In FY 1989 the NIAID plans to award at least two CIRID grants, depending upon the availability of funds. Applications of high scientific merit which cannot be funded under the
announcement could be considered for funding under the Institute's regular research grant programs.

METHOD OF APPLYING

Applications may be submitted by any domestic public or private nonprofit or profit-making organizations. Procedures are outlined in the NIAD Information Brochure on Centers and Program Projects which contains special instructions for preparing applications, review procedures and criteria, and may be obtained from:

Dr. Nirmal Das  
Executive Secretary  
Allergy, Immunology and Transplantation Research Committee  
National Institute of Allergy and Infectious Diseases  
National Institutes of Health  
Westwood Building, Room 706  
Bethesda, Maryland 20892  
Telephone: (301) 496-7966

STAFF CONTACT

A more detailed RFA may be obtained from:

Robert A. Goldstein, M.D., Ph.D.  
Chief, Clinical Immunology and  
Immunopathology Branch  
National Institute of Allergy  
and Infectious Diseases  
Westwood Building, Room 757  
Bethesda, Maryland 20892  
Telephone: (301) 496-7104

THE RFA LABEL AVAILABLE IN THE 9/86 REVISION OF APPLICATION FORM 398 MUST BE AFFIXED TO THE BOTTOM OF THE FACE PAGE. FAILURE TO USE THIS LABEL COULD RESULT IN DELAYED PROCESSING OF YOUR APPLICATION SUCH THAT IT MAY NOT REACH THE REVIEW COMMITTEE IN TIME FOR REVIEW.

NOTICE - MACROMOLECULAR STRUCTURE REFINEMENT WORKSHOP FOR BIOMEDICAL RESEARCHERS

P.T. 42; K.W. 1004000, 0790015, 1014001  
Division of Research Resources  
Application Receipt Date: August 1, 1988

The Pittsburgh Supercomputing Center (PSC) is conducting a two day workshop dealing with refinement of macromolecular structures against diffraction data on October 31 and November 1, 1988. The workshop is funded by a grant from the National Institutes of Health (NIH), Division of Research Resources, Biomedical Research Technology (BRT) Program.

The workshop will deal with the use of supercomputers for structure refinement by restrained least squares, simulated annealing (molecular dynamics) and noncrystallographic symmetry averaging. Descriptions of the various refinement methods will be presented as well as details involving use of local versions of the appropriate programs on currently available supercomputers. Participants are encouraged to bring their own data as part of the workshop and will involve hands-on use of the facilities. Computing time will be made available and the local staff will provide assistance in data preparation such that it should be possible for each participant to deal with his/her own particular application. Workshop leaders: W. Furey, VA Medical Center and University of Pittsburgh; A. Brunger, Yale University; and G. Kamer, Purdue University.

Travel, meal and hotel accommodations are covered for academic participants under the grant. THE DEADLINE FOR THE SUBMISSION OF APPLICATIONS IS AUGUST 1, 1988. Enrollment is limited to 20 participants. The workshop is timed to immediately precede the Pittsburgh Diffraction Conference (November 2-4).
For application forms and additional information, call or write:

Cherolyn Brooks
User Services
Pittsburgh Supercomputing Center
4400 Fifth Avenue
Pittsburgh, Pennsylvania 15213
Telephone: (412) 268-5206
(800) 222-9310 Inside Pennsylvania
(800) 221-1641 Outside Pennsylvania

ERRATUM

INVESTIGATIONS INTO METHODS THAT REPLACE OR REDUCE ANIMALS USED IN RESEARCH OR LESSEN THEIR PAIN AND DISTRESS

P.T. 34; K.W. 0755020, 0780015, 0715150, 1002027

Alcohol, Drug Abuse, and Mental Health Administration

The National Institute on Alcohol Abuse and Alcoholism (NIAAA) and the National Institute on Drug Abuse (NIDA) were inadvertently omitted from the program announcement when it was published in the NIH Guide for Grants and Contracts, Vol. 17, No. 15, Pages 4-6, April 22, 1988. Applicants who are interested in applying for support from NIAAA or NIDA under the subject program announcement should contact:

Dr. Sue Badman
Deputy Director, Division of Basic Research, NIAAA
Parklawn Building, Room 14C-10
5600 Fishers Lane
Rockville, Maryland 20857
Telephone: (301) 443-2530

Dr. Roger Brown
Chief, Neuroscience Research Branch
Division of Preclinical Research, NIDA
Parklawn Building, Room 10A-31
5600 Fishers Lane
Rockville, Maryland 20857
Telephone: (301) 443-6975